Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach ...

Carolina Wealth Advisors, LLC added 102,629 shares of Novo Nordisk A/S, an estimated $6.01 million trade based on the average price for Q3 2025. The trade represented 2.6% of reportable AUM for the ...

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are trading lower Friday morning, continuing an after-hours slide that began Thursday. The decline was sparked by comments from ...

CHICAGO (Reuters) -A federal appeals court on Monday rejected Novo Nordisk's challenge to the U.S. government’s program that gives its Medicare health insurance plan the power to negotiate lower drug ...

NVO trades at a rare dislocation with a forward P/E ~15% below sector and EPS growth ~66% above, primed for the 2026 healthcare re-rating. Its semaglutide engine (Wegovy growth, CagriSema pipeline, ...